A recent study suggests that women who use Depo-Provera may have an elevated risk of slow-growing brain tumors, particularly meningiomas. This finding is significant as it coincides with a wave of lawsuits against Pfizer, the contraceptive’s manufacturer, alleging that the company was aware of these risks.
Depo-Provera, which is a form of injectable contraceptive containing the synthetic hormone depot-medroxyprogesterone acetate (DMPA), works by preventing the ovaries from releasing eggs to avoid pregnancy. It’s notable that around 25% of sexually active women in the U.S. utilize this form of contraception, which remains effective for about three months.
In the research involving over 61 million female patients, the data revealed that women using DMPA faced double the chances of being diagnosed with meningioma compared to those who did not use hormonal contraceptives.
While meningiomas are typically benign, they can still lead to complications by pressing against nerves or other brain structures. Interestingly, this condition is more prevalent in women than men, possibly due to hormones that can aid in tumor growth.
Researchers from Cleveland Clinic and Case Western Reserve University noted that the risk heightened for women starting DMPA after 31 or using it for more than four years. In the study, they observed that the chance of a subsequent meningioma diagnosis was notably greater for those with longer exposure to the medication.
It’s important to mention that this study only indicates a correlation and did not establish a direct cause-and-effect relationship between DMPA and meningiomas.
Medroxyprogesterone acetate was initially developed in 1954 for treating endometriosis and other gynecological issues. Although the FDA was skeptical about its safety for contraceptive use for a long time, it eventually approved Depo-Provera in 1992 after additional research and trials in other countries.
In 2004, a “black box” warning was added, cautioning about possible severe bone density loss linked to prolonged use. Adding to the controversy, a recent study published in BMJ found that women on Depo-Provera for over a year were 5.6 times more likely to develop meningiomas.
Currently, Pfizer faces over 1,200 federal lawsuits related to Depo-Provera, with plaintiffs claiming the company did not adequately inform them about the risks of meningiomas.
One plaintiff, Robin Phillip from Louisiana, shared her experience of developing an intracranial meningioma that resulted in vision loss and mobility issues. Her attorney noted the profound impact on the lives of many women who underwent similar challenges.
According to reports, Phillips’ lawsuit references studies dating back to the early 1980s that established a link between progesterone and meningiomas, suggesting that Pfizer should have been proactive in investigating Depo-Provera’s risks.
A Pfizer representative has dismissed these allegations as unfounded, asserting their commitment to defending against them. The company has taken steps to have the FDA update the product’s warning label, though the request was denied based on existing research.
Overall, Pfizer maintains that Depo-Provera remains an essential and safe option for many women globally in managing their reproductive health.
